)

ProQR Therapeutics (PRQR) investor relations material
ProQR Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Submitted Clinical Trial Application for AX-0810, targeting NTCP in cholestatic diseases, with first-in-human Phase 1 trial expected to start in the Netherlands and initial data anticipated in Q4 2025.
Advancing AX-2402 program for Rett Syndrome toward clinical candidate selection in 2025; additional pipeline programs progressing, including AX-2911 for MASH and AX-1412 for cardiovascular disease.
Hosted and participated in key scientific conferences, highlighting advances in Axiomer RNA editing platform, and announced new CFO and CMO appointments to support clinical stage transition.
Financial highlights
Cash and cash equivalents stood at €119.8 million as of June 30, 2025, down from €149.4 million at December 31, 2024.
Net cash used in operating activities was €27.2 million for the first half of 2025, compared to €21.4 million in the same period last year.
R&D costs increased to €23.7 million for the six months ended June 30, 2025, from €16.3 million year-over-year; G&A costs rose to €8.1 million from €6.5 million.
Net loss for the six-month period was €22.3 million (€0.21 per diluted share), compared to €10.4 million (€0.13 per diluted share) in the prior year.
Achieved $2.0 million (~€1.8 million) in milestone payments from Eli Lilly collaboration in H1 2025.
Outlook and guidance
Initial Phase 1 data for AX-0810 expected in Q4 2025; clinical candidate selection for AX-2402 and AX-2911 anticipated in 2025.
Virtual Analyst and Investor Event planned for fall 2025 to provide updates on AX-0810 trial design, data expectations, and broader pipeline progress.
Cash runway projected into mid-2027, excluding potential additional milestones from the Lilly partnership.
Next ProQR Therapeutics earnings date

Next ProQR Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage